DRUGS MADE IN AMERICA ACQUIS

DMIINASDAQ

🏆 #2656 by market capUS Equity

$10.14▲ $0.02 (+0.20%)

Live

1h—

24h▲ 0.2%

7d▲ 0.3%

14d▲ 0.2%

30d▲ 0.4%

1y—

🏦Market Cap

$646M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $10.04 – $10.29
52-Week Range: $9.86 – $10.20
Volume: $2.32B
Avg Volume: $1.63B
Shares Outstanding: 63.7M
Next Earnings: Sep 10, 2026

Fundamentals Snapshot

Annual Revenue: $51M
Last Q Revenue: $12M
P/E Ratio: 75.1
P/S Ratio: —
EPS (TTM): $0.74
Dividend Yield: —

Why Investors Own DMII

✓High-growth profile — revenue up +24.1% YoY with expanding US Equity exposure.
✓Healthy economics — 36% gross margin and 5% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$51M▲ +27.2% YoY

Gross Margin (TTM)

35.9%▲ +4.0% YoY

Operating Income (TTM)

$9M▲ +27.2% YoY

Free Cash Flow (TTM)

$3M▲ +27.2% YoY

About DRUGS MADE IN AMERICA ACQUIS

Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.

🦦